| Biomarker ID | 1625 |
| PMID | 31031850 |
| Year | 2019 |
| Biomarker | CCNB1 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.464 |
| Effect on Pathways | Pathways include: T cell receptor regulation of apoptosis, Cell cycle, Oncostatin M, Chk1/Chk2(Cds1)-mediated inactivation of cyclin B-Cdk1 complex, p53 signaling pathway |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.5977 |
| Accuracy | NA |
| Level Of Significance | p=0.0166 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |